Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial Post author:admin Post published:March 12, 2025 Post category:uncategorized NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. You Might Also Like Writing by hand enhances brain function critical for learning December 9, 2024 Brainstem damage found to be behind long-lasting effects of severe Covid-19 October 8, 2025 Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial shows February 14, 2025
Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial shows February 14, 2025